Ractigen Therapeutics
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2016-09-02
- Employees
- 51
- Market Cap
- -
- Website
- https://www.ractigen.com
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Ractigen Therapeutics.
- Target Recruit Count
- 32
- Registration Number
- NCT06556394
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, China
🇨🇳West China Hospital of Sichuan University, Chengdu, China
🇨🇳The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ractigen Therapeutics.
- Target Recruit Count
- 15
- Registration Number
- NCT06351904
- Locations
- 🇦🇺
The Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺Peninsula & South Eastern Haematology and Oncology Group, Melbourne, Victoria, Australia
🇦🇺GenesisCare North Shore, St Leonards, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath